Swiss Dental Firm vVARDIS Raises $175 Million in NYSE IPO at $18
vVARDIS priced its IPO at $18 a share and raised about $175 million on the NYSE. How many shares were sold, which banks ran the deal and what comes next.
vVARDIS Holding AG, a Swiss company that works on regenerating tooth enamel, priced its initial public offering at $18 a share, according to 24/7 Wall St. The sale raised roughly $175 million, and the stock is listing on the New York Stock Exchange under the ticker VVVV.
Investors who were allotted stock in the offering paid $18. Anyone else buys at the market price once the exchange completes the opening auction for a newly listed stock, and that price can sit above or below the offer.
How many shares vVARDIS sold and which banks ran the sale
The offering covered 9,722,223 shares, 24/7 Wall St. reported. Pricing is the last step before trading starts: the company and its banks settle on one figure per share after collecting orders from investors.
Five banks handled that work as bookrunners, the firms that gather the orders and decide who receives stock. They were Goldman Sachs, J.P. Morgan, UBS, Deutsche Bank and William Blair.
The outlet described the deal as one of the larger medical technology debuts on the NYSE this year. It also read the size of the bank group as evidence of demand from institutions such as investment funds, and wrote that underwriters of that standing do not usually gather for an offering they expect to struggle. That reading belongs to the outlet. The level of orders the banks received was not disclosed.
A business between dentistry and biotech
vVARDIS focuses on enamel regeneration, meaning products intended to restore the hard outer layer of a tooth. 24/7 Wall St. placed the category where dentistry meets biotechnology and said it is drawing more attention from consumers and from clinicians who want restorative treatments.
What it means for shareholders and for other medtech listings
An IPO turns a privately held company into one whose shares can be bought and sold by anyone with a brokerage account. For vVARDIS, the offer price of $18 becomes the reference point for everything that follows. New shareholders can compare what they pay with what institutions paid in the offering.
24/7 Wall St. argued that the first trade carries weight beyond this one company. In its view, an opening at or above $18 would make conditions easier for the medical technology companies waiting to list after vVARDIS, while a weak start would tighten conditions for that whole group. The outlet presented this as its own assessment of the IPO calendar.
What to watch in the first trading sessions
The opening price compared with the $18 offer is the first figure to check. The second, according to 24/7 Wall St., is the behavior of the institutions that received allocations, the blocks of stock handed out by the bookrunners before trading began.
If those holders keep their shares through the first sessions, the outlet wrote, it would suggest the price reflected real conviction. Heavy selling would suggest the deal only cleared the minimum needed to get done.
Source: 24/7 Wall St.


